Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors Globe Newswire: September 1, 2022 Read More
Go back to Press Page
